Lupin Launches Liraglutide Injection in US
Liraglutide Injection, 18 mg/3 mL (6 mg/mL) single-patient-use pre-filled pen is bioequivalent to Victoza injection, 18 mg/3 mL (6 mg/mL) of Novo Nordisk Inc.
Global Pharma | 04/10/2025 | By Dineshwori | 334
Titan Pharmaceuticals Completes Merger with Black Titan and TalenTec
Titan Pharmaceuticals has completed its merger with Black Titan Corporation, a Cayman Islands exempted company, and TalenTec, a Malaysian private limited company. The transaction closed successfully on October 1, 2025, making Titan a wholly owned subsidiary of Black Titan.
Global Pharma | 04/10/2025 | By Dineshwori | 865
Daiichi Sankyo Establishes Third Research Institute in San Diego
Daiichi Sankyo Research Institutes, located in Boston, Munich and San Diego, are advancing the vision of Daiichi Sankyo to foster the development of next-generation medicines.
Global Pharma | 04/10/2025 | By Dineshwori | 201
India's USD 12 Billion MedTech Sector Set to Surge to USD 50 billion by 2030: Dr Jitendra Singh
Union Minister Dr. Jitendra Singh noted that institutions like SCTIMST, with recognition from WHO and collaborations with national agencies such as ICMR, DBT, CSIR, DRDO and INSA, can contribute to India’s emergence as a global hub for cost-effective healthcare and medical tourism by 2047.
Global Pharma | 04/10/2025 | By Dineshwori | 245
Celltrion Launches Tocilizumab Biosimilar AVTOZMA IV in the US Market
AVTOZMA is Celltrion's fifth immunology biologic and seventh biosimilar approved by the US FDA. It will be available in the same presentations as its reference product, Actemra (tocilizumab).
Global Pharma | 03/10/2025 | By Dineshwori | 609
Lupin Launches Generic Xarelto Rivaroxaban Oral Suspension in US
Global pharma major Lupin has announced the launch of Rivaroxaban for Oral Suspension, 1 mg/mL, in the United States.
Global Pharma | 03/10/2025 | By Dineshwori | 471
Amcor to Showcase Sustainable and Patient-Centric Packaging Innovations at CPHI Frankfurt 2025
At CPHI Frankfurt 2025, Amcor will highlight its extensive portfolio of rigid and flexible packaging solutions, including ClariPPil jars and OSD bottles for oral solid dose applications, alongside its AmSky and high-shield pharma laminates.
Global Pharma | 03/10/2025 | By Dineshwori | 555
FDA Approves Novartis's Rhapsido as First Oral BTK Inhibitor for Chronic Spontaneous Urticaria
The US Food and Drug Administration (FDA) has approved Novartis’ Rhapsido (remibrutinib) as an oral treatment for adult patients with chronic spontaneous urticaria (CSU) who continue to experience symptoms despite H1 antihistamine therapy.
Global Pharma | 03/10/2025 | By Dineshwori | 563
Novavax, Sanofi Deepen Partnership to Include Matrix-M in Pandemic Influenza Vaccine Programme
The expanded partnership allows Sanofi to use Novavax’s Matrix-M adjuvant in its pandemic influenza vaccine candidate programme.
Global Pharma | 01/10/2025 | By Dineshwori | 378
Artemis Acquires Millrock Technology
Under Artemis' ownership, Millrock will continue to operate as an independent company from its facility in Kingston, New York, serving a global customer base.
Global Pharma | 01/10/2025 | By Dineshwori | 422
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy